Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 3/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644210 | 0.87 | CSNK2A2 (0.33) | CSNK2A2CSNK2A1MAPK1TGFBR1PDE4A | |
| SCHEMBL2358715 | 0.83 | CSNK2A2 (0.33) | CSNK2A2CSNK2A1IRAK4 | |
| SCHEMBL25274583 | 0.74 | HCAR3 (0.41) | — | |
| SCHEMBL30968211 | 0.74 | HCAR3 (0.41) | — | |
| SCHEMBL25678250 | 0.73 | KDM4E (0.36) | CSNK2A2CSNK2A1 | |
| SCHEMBL2356865 | 0.72 | PRKCQ (0.38) | CSNK2A2PDE4D | |
| SCHEMBL3018033 | 0.71 | KDM4E (0.42) | MAPK1 | |
| SCHEMBL3309226 | 0.70 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1TGFBR1IRAK4ERN1 | |
| SCHEMBL19742684 | 0.69 | CSNK2A2 (0.49) | CSNK2A2CSNK2A1ERN1 | |
| SCHEMBL2357939 | 0.68 | CSNK2A2 (0.37) | CSNK2A2CSNK2A1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | CSNK2A2 135/4885CSNK2A1 88/4885MAPK1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.